Clinical efficacy of Shuxin Oral Liquid combined with conventional western medicine in the treatment of stable coronary heart disease with anxiety based on "psycho-cardiology disease" theory

WANG Junli; LI Liwei; TIAN Qiangqiang; ZHANG Beibei; GONG Xue; XU Jinmei; MEI Junhua

doi:10.16306/j.1008-861x.2021.05.003

您当前的位置：

首页 >

文章列表页 >

Clinical efficacy of Shuxin Oral Liquid combined with conventional western medicine in the treatment of stable coronary heart disease with anxiety based on "psycho-cardiology disease" theory

Clinical Research | 更新时间：2022-09-09

- Clinical efficacy of Shuxin Oral Liquid combined with conventional western medicine in the treatment of stable coronary heart disease with anxiety based on "psycho-cardiology disease" theory
- Academic Journal of Shanghai University of Traditional Chinese Medicine Vol. 35, Issue 5, Pages: 14-19(2021)
- 作者机构：
  
  1.湖北中医药大学（湖北　武汉　430065）
  2.武汉市第一医院神经内科（湖北　武汉　430022）
  3.武汉市第一医院心血管内科（湖北　武汉　430022）
  4.湖北省中医院心血管内科（湖北　武汉　430061）
  5.湖北省中医院神经内科（湖北　武汉430061）
- 作者简介：
- 基金信息：
- DOI：10.16306/j.1008-861x.2021.05.003
  CLC：
扫描看全文
WANG Junli, LI Liwei, TIAN Qiangqiang, et al. Clinical efficacy of Shuxin Oral Liquid combined with conventional western medicine in the treatment of stable coronary heart disease with anxiety based on "psycho-cardiology disease" theory. [J]. Academic Journal of Shanghai University of Traditional Chinese Medicine 35(5):14-19(2021)
DOI：

WANG Junli, LI Liwei, TIAN Qiangqiang, et al. Clinical efficacy of Shuxin Oral Liquid combined with conventional western medicine in the treatment of stable coronary heart disease with anxiety based on "psycho-cardiology disease" theory. [J]. Academic Journal of Shanghai University of Traditional Chinese Medicine 35(5):14-19(2021) DOI： 10.16306/j.1008-861x.2021.05.003.

摘要

目的：,2,基于中医学“双心疾病”理论，探讨舒心口服液联合西医常规疗法治疗稳定性冠心病（SCHD）合并焦虑的临床疗效。,方法：,2,纳入90例SCHD合并焦虑患者，随机分为治疗组和对照组，每组各45例。两组患者均给予常规西药治疗，同时治疗组患者给予舒心口服液治疗，治疗周期为12周。治疗前及治疗4周、12周时，记录患者的心绞痛发作次数及硝酸甘油用量，并采用自拟中医证候积分量表、汉密尔顿焦虑量表（HAMA）、西雅图心绞痛调查表（SAQ）评估患者的临床症状、情绪状态及生活质量。,结果：,2,研究过程中，治疗组2例患者、对照组2例患者被剔除或脱落，最终治疗组43例、对照组43例患者纳入统计分析。①治疗4周、12周时，两组患者的心绞痛发作次数及硝酸甘油用量较治疗前均明显减少（,P,<,0.05），且治疗组患者的心绞痛发作次数及硝酸甘油用量较对照组亦明显减少（,P,<,0.05）。②治疗4周、12周时，治疗组患者的HAMA总分及心血管系统因子评分较治疗前均明显降低（,P,<,0.05），且治疗组患者的评分较对照组亦明显降低（,P,<,0.05）。③治疗4周、12周时，两组患者的中医证候总积分及胸痛、心悸、气短积分较治疗前均明显减少（,P,<,0.05），且治疗组患者的积分均低于对照组（,P,<,0.05）。④治疗4周、12周时，两组患者的SAQ各维度积分较治疗前均明显升高（,P,<,0.05），且治疗组患者的SAQ各维度积分较对照组亦明显升高（,P,<,0.05）。,结论：,2,基于中医学“双心疾病”理论，以舒心口服液联合西医常规疗法治疗SCHD合并焦虑患者，可明显改善患者的临床症状及焦虑情绪，提高患者的生活质量。

Abstract

Objective:,2,To explore the clinical efficacy of Shuxin Oral Liquid combined with conventional western medicine in the treatment of stable coronary heart disease(SCHD) with anxiety based on "psycho-cardiology disease" theory in traditional Chinese medicine(TCM) .,Methods:,2,A total of 90 SCHD patients with anxiety were included and randomly divided into the treatment group and control group, 45 cases in each group.The patients in both groups were treated with conventional western medicine, meanwhile the patients in the treatment group were treated with Shuxin Oral Liquid.The treatment course was 12 weeks.Before treatment and 4 and 12 weeks after treatment, the frequency of angina attack and the nitroglycerin dosage were recorded, and the self-made TCM syndrome score scale, Hamilton anxiety(HAMA) scale and Seattle angina questionnaire(SAQ) were applied to evaluate the clinical symptoms, emotional state and quality of life.,Results:,2,During the study, 2 patients in the treatment group and 2 patients in the control group were eliminated or fell off.Finally 43 cases in the treatment group and 43 cases in the control group were included for the statistical analysis.①Four and twelve weeks after treatment, the frequency of angina attack and the nitroglycerin dosage were significantly reduced in both groups compared with those before treatment(,P,<,0.05), and the frequency of angina attack and the nitroglycerin dosage in the treatment group were significantly less than those in the control group(,P,<,0.05) .②Four and twelve weeks after treatment, the total score and cardiovascular system factor score of HAMA were significantly decreased in the treatment group compared with those before treatment(,P,<,0.05), and the scores of the treatment group were obviously lower than those of the control group(,P,<,0.05) .③Four and twelve weeks after treatment, the total score of TCM syndromes and the scores of chest pain, palpitation and short breath were significantly reduced in both groups compared with those before treatment(,P,<,0.05), and the scores of the treatment group were lower than those of the control group(,P,<,0.05) .④Four and twelve weeks after treatment, all dimension scores of SAQ were significantly increased in both groups compared with those before treatment(,P,<,0.05), and all dimension scores of SAQ in the treatment group were significantly higher than those in the control group(,P,<,0.05) .,Conclusion:,2,Based on the "psycho-cardiology disease" theory of TCM, Shuxin Oral Liquid combined with conventional western medicine can obviously improve the clinical symptoms and anxiety and enhance the quality of life in treating SCHD patients with anxiety.

关键词

稳定性冠心病焦虑双心疾病舒心口服液中西医结合

Keywords

stable coronary heart diseaseanxietypsycho-cardiology diseaseShuxin Oral Liquidintegrated traditional Chinese and western medicine

references

胡盛寿，高润霖，刘力生，等.《中国心血管病报告2018》概要[J]. 中国循环杂志，2019，34(3)： 209-220.

汤柏赞，张靖婧，邵海峰，等. 齐齐哈尔市≥20岁城市居民冠心病患病现状及危险因素分析[J]. 中国公共卫生，2017，33(6)： 985-987.

中华医学会心血管病学分会介入心脏病学组，中华医学会心血管病学分会动脉粥样硬化与冠心病学组，中国医师协会心血管内科医师分会血栓防治专业委员会，等. 稳定性冠心病诊断与治疗指南[J]. 中华心血管病杂志，2018，46(9)： 680-694.

MAYER O，BRUTHANS J，SEIDLEROVÁ J. et al. Mood disorders impaired quality of life but not the mortality or morbidity risk in stable coronary heart disease patients[J]. Acta Cardiol，2019，75(7)： 1-9.

北京高血压防治协会，北京糖尿病防治协会，北京慢性病防治与健康教育研究会，等. 基层心血管病综合管理实践指南2020[J]. 中国医学前沿杂志（电子版），2020，12(8)： 1-73.

PIMPLE P，LIMA B B，HAMMADAH M，et al. Psychological Distress and Subsequent Cardiovascular Events in Individuals With Coronary Artery Disease [J]. J Am Heart Assoc，2019，8(9)： e011866.

魏娜，汤诺，高继梅，等. 舒心饮结合西医常规疗法治疗冠状动脉硬化性心脏病合并慢性心力衰竭的临床观察[J]. 上海中医药大学学报，2021，35(3)： 17-22.

STEWART R A H，COLQUHOUN D M，MARSCHNER S L，et al. Persistent psychological distress and mortality in patients with stable coronary artery disease[J]. Heart，2017，103(23)： 1860-1866.

中国中西医结合学会心血管病专业委员会双心学组. 双心疾病中西医结合诊治专家共识[J]. 中国全科医学，2017，20(14)： 1659-1662.

CAMPEAU L. Letter： Grading of angina pectoris[J]. Circulation，1976，54(3)： 522-523.

中华医学会神经病学分会神经心理学与行为神经病学组. 综合医院焦虑、抑郁与躯体化症状诊断治疗的专家共识[J]. 中华神经科杂志，2016，49(12)： 908-916.

中国中医科学院. 中医循证临床实践指南中医内科[M]. 北京：中国中医药出版社，2011.

国家中医药管理局. 中医病证诊断疗效标准[M]. 北京：中国医药科技出版社，2012.

许贤豪. 神经心理量表检测指南[M]. 北京：中国协和医科大学出版社，2007： 85.

史周华，张雪飞. 中医药统计学[M]. 北京：科学出版社，2009：155.

刘淑红. 西雅图心绞痛量表（SAQ）中文译本的信度、效度、反应度[D]. 天津：天津医科大学，2003.

毕颖裴，王贤良，赵志强，等. 冠心病现代中医证候特征的临床流行病学调查[J]. 中医杂志，2017，58(23)： 2013-2019.

EMDIN C A，ODUTAYO A，WONG C X，et al. Meta-Analysis of Anxiety as a Risk Factor for Cardiovascular Disease[J]. Am J Cardiol，2016，118(4)： 511-519.

葛均波，徐永健，王辰. 内科学[M]. 9版. 北京：人民卫生出版社，2018： 218.

中国中医药研究促进会中西医结合心血管病预防与康复专业委员会. 稳定性冠心病中西医结合康复治疗专家共识[J]. 中西医结合心脑血管病杂志，2019，17(3)： 321-329.

王阶，李军，姚魁武，等. 冠心病心绞痛证候要素与应证组合研究[J]. 中医杂志，2007，48(10)： 920-922.

国家卫生计生委合理用药专家委员会，中国药师协会. 冠心病合理用药指南（第2版）[J]. 中国医学前沿杂志（电子版），2018，10(6)： 1-130.

贺雅琪，段骄，林炜基，等. 基于生活质量改善效应的岭南中医治疗慢性稳定性冠心病的临床研究[J]. 中华中医药学刊，2019，37(8)： 1840-1843.

姜奕慈. 基于双心模式探究疏调汤治疗稳定性冠心病伴焦虑抑郁状态的临床研究[D]. 昆明：云南中医药大学，2020.

Views

304

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical observation on chemotherapy combined with modified Yiyanxiao Formula in treating patients of pancreatic cancer with peritoneal metastasis

Effect of Renal Failure Ⅱ Prescription granule combined with empagliflozin on proteinuria and renal function in patients with CKD at stages 2⁃3

Expert consensus on integrated traditional Chinese and western medicine clinical diagnosis and treatment of brain glioma （Shanghai）

Clinical observation of Shenshuaiyi Formula in treatment of chronic kidney disease at stage 4 combined with chronic heart failure

Clinical research on Xiaobai Decoction in the treatment of chronic glomerulonephritis (CKD at stages 1-2) with syndrome of spleen and kidney qi deficiency and stagnant dampness-heat

Related Author

No data

Related Institution

Shanghai University of Traditional Chinese Medicine

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

Department of Nephrology， Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine； Shanghai Clinical Key Laboratory of Traditional Chinese Medicine； Key Laboratory of Liver and Kidney Diseases， Ministry of Education

Yidan Nursing Home

Inheritance Studio of Ye Jinghua National Famous Doctor of Traditional Chinese Medicine

⁰